How has the recent FDA approval of tovorafenib impacted your treatment decisions for pediatric patients with relapsed/refractory low-grade glioma?
Is it merely another option to try or will it become the standard choice for patients experiencing relapsed/refractory disease?
Community PollStarted
Which treatment modality do you prefer for patients with relapsed/refractory low grade glioma?
5 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Pediatric Hematology/Oncology · The Brain Tumor Institute
Answered on
With the FDA approval, and given the tolerability of therapy and the pediatric friendly once weekly dosing and formulations, I will prescribe tovorafenib regularly for my patients with relapsed refractory low grade glioma. I do think it will become a standard choice in this setting. That said, given...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Toronto Faculty of Medicine
Answered on
If we look at the current landscape, tovorafenib is - in the USA - the only targeted therapy approved for the second-line treatment of BRAF-altered pLGG. So, this is a great opportunity for patients. There is no MEK inhibitor approved in this setting (trametinib, selumetinib, binimetinib, mirdametin...
Join for free or sign in to see the full answer